Learn how the FIDELITY risk model helps clinicians predict hyperkalaemia in CKD and diabetes-read on for clinical insights.

This article sheds light on Type 2 diabetes, and the importance of holistic management and culturally competent care.​ ...

The study published in the Lancet on April 30 was the outcome of research, which was funded in part by the China's government ...

A new study reveals that semaglutide, a common diabetes medication, may effectively treat fatty liver disease, offering hope ...

Though retrospective, the findings provide ‘compelling’ evidence that GLP-1 receptor agonists may help prevent development ...

Semaglutide is the key component of weight loss and diabetes drugs like Ozempic and Wegovy, and an international team of ...

Lifestyle and dietary habits can have a serious impact on our kidneys. But studies show that making simple changes can offer protection and improve our health ...

The Task Force assembles leading Texas nephrologists, nurses, dietitians, educators, and other CKD experts to review the minimum practice standards data from state agency programs, health systems, and ...

A large U.S. cohort study found that post-acute symptoms after COVID-19 vary by initial disease severity, age, sex, and comorbidities. Compared to influenza and pneumonia, long COVID presented with ...

Combined use of SGLT2 inhibitors and GLP-1 receptor agonists also significantly increased the risk for falls. (HealthDay News) — Sodium-glucose cotransporter 2 (SGLT2) inhibitor use is an independent ...

Tirzapetide dose escalation schedules were slower in the real-world than clinical settings among individuals with obesity without T2D.

Researchers at Pennington Biomedical Research Center have revealed critical insights into how impaired mitochondrial dynamics ...